170 related articles for article (PubMed ID: 15870670)
1. Immunodeficiency in children with acute lymphoblastic leukemia after completion of modern aggressive chemotherapeutic regimens.
Brodtman DH; Rosenthal DW; Redner A; Lanzkowsky P; Bonagura VR
J Pediatr; 2005 May; 146(5):654-61. PubMed ID: 15870670
[TBL] [Abstract][Full Text] [Related]
2. Revaccination of children after completion of standard chemotherapy for acute leukemia.
Patel SR; Ortín M; Cohen BJ; Borrow R; Irving D; Sheldon J; Heath PT
Clin Infect Dis; 2007 Mar; 44(5):635-42. PubMed ID: 17278052
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.
Möricke A; Zimmermann M; Reiter A; Gadner H; Odenwald E; Harbott J; Ludwig WD; Riehm H; Schrappe M
Klin Padiatr; 2005; 217(6):310-20. PubMed ID: 16307416
[TBL] [Abstract][Full Text] [Related]
4. Humoral immunity to diphtheria, tetanus, measles, and hemophilus influenzae type b in children with acute lymphoblastic leukemia and response to re-vaccination.
Zengin E; Sarper N
Pediatr Blood Cancer; 2009 Dec; 53(6):967-72. PubMed ID: 19544393
[TBL] [Abstract][Full Text] [Related]
5. Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy.
Zignol M; Peracchi M; Tridello G; Pillon M; Fregonese F; D'Elia R; Zanesco L; Cesaro S
Cancer; 2004 Aug; 101(3):635-41. PubMed ID: 15274078
[TBL] [Abstract][Full Text] [Related]
6. Prothrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli asparaginase (COALL-92 and 97 protocols).
Mauz-Körholz C; Junker R; Göbel U; Nowak-Göttl U
Thromb Haemost; 2000 Jun; 83(6):840-3. PubMed ID: 10896235
[TBL] [Abstract][Full Text] [Related]
7. Diphtheria (D) and tetanus (T) antibody values in children with acute lymphoblastic leukaemia (ALL) after treatment according to Co-ALL 05/92.
Calaminus G; Hense B; Laws HJ; Groeger M; MacKenzie CR; Göbel U
Klin Padiatr; 2007; 219(6):355-60. PubMed ID: 18050047
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid excitatory amino acids and tau protein in children with acute lymphoblastic leukemia treated according to the BFM protocol.
Holownia A; Trofimiuk E; Krawczuk-Rybak M; Jakubow P; Kaliszewski J; Muszynska-Roslan K; Braszko JJ
Acta Haematol; 2004; 112(4):222-4. PubMed ID: 15564737
[No Abstract] [Full Text] [Related]
9. Longitudinal assessment of immunological status and rate of immune recovery following treatment in children with ALL.
Kosmidis S; Baka M; Bouhoutsou D; Doganis D; Kallergi C; Douladiris N; Pourtsidis A; Varvoutsi M; Saxoni-Papageorgiou F; Vasilatou-Kosmidis H
Pediatr Blood Cancer; 2008 Mar; 50(3):528-32. PubMed ID: 17853465
[TBL] [Abstract][Full Text] [Related]
10. Incidence and outcome of TCF3-PBX1-positive acute lymphoblastic leukemia in Austrian children.
Kager L; Lion T; Attarbaschi A; Koenig M; Strehl S; Haas OA; Dworzak MN; Schrappe M; Gadner H; Mann G;
Haematologica; 2007 Nov; 92(11):1561-4. PubMed ID: 18024406
[TBL] [Abstract][Full Text] [Related]
11. Atypical pyoderma gangrenosum as a manifestation of childhood acute lymphoblastic leukemia.
Bakhshi S; Sethuraman G; Singh MK; Arya LS
Pediatr Dermatol; 2005; 22(6):543-5. PubMed ID: 16354258
[TBL] [Abstract][Full Text] [Related]
12. Humoral immune response after post-chemotherapy booster diphtheria-tetanus-pertussis vaccine in pediatric oncology patients.
Cheng FW; Leung TF; Chan PK; Lee V; Shing MK; Chik KW; Yuen PM; Li CK
Pediatr Blood Cancer; 2009 Feb; 52(2):248-53. PubMed ID: 18937325
[TBL] [Abstract][Full Text] [Related]
13. Herpes simplex virus reactivation and disease during treatment for childhood acute lymphoblastic leukemia.
Lauten M; Güttel C; Härtel C; Erdlenbruch B
Klin Padiatr; 2014 May; 226(3):188-9. PubMed ID: 24158893
[No Abstract] [Full Text] [Related]
14. Symptomatic hypoglycemia in children receiving oral purine analogues for treatment of childhood acute lymphoblastic leukemia.
Ziino O; Russo D; Orlando MA; Benigno V; Locatelli F; Aricò M
Med Pediatr Oncol; 2002 Jul; 39(1):32-4. PubMed ID: 12116076
[TBL] [Abstract][Full Text] [Related]
15. [Acute pancreatitis during chemotherapy of acute lymphoblastic leukaemia complicated with pseudocyst].
Sikorska-Fic B; Stańczak E; Matysiak M; Kamiński A
Med Wieku Rozwoj; 2008; 12(4 Pt 2):1051-5. PubMed ID: 19531825
[TBL] [Abstract][Full Text] [Related]
16. Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration.
Nowak-Göttl U; Ahlke E; Fleischhack G; Schwabe D; Schobess R; Schumann C; Junker R
Blood; 2003 Apr; 101(7):2529-33. PubMed ID: 12517808
[TBL] [Abstract][Full Text] [Related]
17. Incidence and Risk Factors for Hypertension During Childhood Acute Lymphoblastic Leukemia Therapy.
Malhotra P; Kapoor G; Jain S; Garg B
Indian Pediatr; 2018 Oct; 55(10):877-879. PubMed ID: 29941701
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of renal function in Turkish children receiving BFM-95 therapy for acute lymphoblastic leukemia.
Kaya Z; Gursel T; Bakkaloglu SA; Kocak U; Atasever T; Oktar SO
Pediatr Hematol Oncol; 2007 Jun; 24(4):257-67. PubMed ID: 17613868
[TBL] [Abstract][Full Text] [Related]
19. Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy.
Aricò M; Valsecchi MG; Rizzari C; Barisone E; Biondi A; Casale F; Locatelli F; Lo Nigro L; Luciani M; Messina C; Micalizzi C; Parasole R; Pession A; Santoro N; Testi AM; Silvestri D; Basso G; Masera G; Conter V
J Clin Oncol; 2008 Jan; 26(2):283-9. PubMed ID: 18182669
[TBL] [Abstract][Full Text] [Related]
20. [Results of treatment of children with acute lymphoblastic leukemia with a modified BFM protocol].
Janić D; Dokmanović L; Jovanović N; Skorić D; Lazić J
Srp Arh Celok Lek; 2004 Oct; 132 Suppl 1():17-22. PubMed ID: 15615459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
